結核菌検査市場：セグメント別規模、シェア、法規制、償還、2036年までの予測

結核菌は、結核菌複合体と呼ばれる菌種群によって引き起こされる細菌感染症です。結核感染には様々なタイプがあります。一次性結核は無症状の場合もあり、皮膚テストが陽性でなければわからないこともあります。一次結核は宿主の免疫反応によって制限され、臨床症状を伴わない潜伏感染となります。潜伏感染から活動性感染に発展するケースはあまりありません。活動性結核患者は、咳、体重減少、寝汗、微熱、呼吸困難、リンパ節腫脹、胸痛、さらには肺炎や喘息を呈します。潜在性結核菌は、患者の中で休眠状態にある結核菌感染症です。高リスクの患者では感染が再活性化する可能性があり、治療開始を検討するために診断のための追加検査が必要です。

結核菌検査は、喀痰サンプルの分析を通じて、活動型および潜伏型の結核を検出するために実施されます。従来の結核菌感染症の診断は、喀痰サンプルの塗抹陽性、培養、胸部X線撮影に依存していました。迅速診断のためには、ポリメラーゼ連鎖反応（PCR）のような核酸増幅検査、酵素結合免疫吸着測定法（ELISA）のような免疫ベースのアッセイ、皮膚パッチテスト、迅速培養システムが実施されます。

当レポートは、世界の結核菌検査市場について詳細に考察し、市場における競合情勢、SWOT分析、2036年までの市場予測、地域、国別の動向などを提供しています。

目次

現在上市されている結核菌検査と競合情勢

• 主要な業界動向の洞察
• 結核菌検査のセグメント別総市場収益と2015年～2036年の市場展望
• 件数、平均販売価格、市場価値に関する詳細データ

世界、地域、国別の洞察

• 結核菌検査市場のSWOT分析
• 結核菌検査市場に関する競合力学の洞察と動向
• 国別の医療制度の概要
• 国別の償還政策
• 国別の医療技術に関する規制の状況

Mycobacterium Tuberculosis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.

Mycobacterium tuberculosis is a bacterial infection that can be caused by group of Mycobacterial species referred to as Mycobacterium tuberculosis complex. Tuberculosis infection can be of many different types. Primary tuberculosis may be asymptomatic and may only be recognized by a positive skin test. The primary tuberculosis can be limited by the host immune response leading to latent infection without clinical symptoms. The infection develops into active infection in few cases. Patients with active tuberculosis present with coughing, weight loss, night sweats, low-grade fever, dyspnea, lymphadenopathy, chest pain, and even pneumonia or phthisis. Latent Mycobacterium tuberculosis is a Mycobacterial infection that lies dormant in the patient. The infection can reactivate in high-risk patients and warrant an additional test for diagnosis to consider initiating treatment.

Mycobacterium tuberculosis tests are carried out to detect both active and latent forms of tuberculosis, through analysis of sputum samples. Traditional diagnosis of Mycobacterial infections depends upon smear positivity in sputum samples, culture and chest radiography. For rapid diagnosis, nucleic acid amplification tests such as polymerase chain reaction (PCR), immune-based assays such as enzyme-linked immunosorbent assay (ELISA), skin patch test and rapid culture systems are performed.

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Mycobacterium Tuberculosis Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Mycobacterium Tuberculosis Tests market revenue by segment and market outlooks from 2015-2036.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Mycobacterium Tuberculosis Tests market.
• Competitive dynamics insights and trends provided for Mycobacterium Tuberculosis Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Companies covered: Qiagen NV, Oxford Immunotec Ltd, Cepheid Inc, Molbio Diagnostics Pvt Ltd, Gen-Probe Inc., Roche Diagnostics International Ltd and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Mycobacterium Tuberculosis Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving Mycobacterium Tuberculosis Tests.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Mycobacterium Tuberculosis Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Mycobacterium Tuberculosis Tests market from 2015-2036.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.